Charcot-Marie-Tooth hereditary neuropathy revealed after administration of docetaxel in advanced breast cancer

Hampig Raphael Kourie, Nicolas Mavroudakis, Philippe Aftimos, Martine Piccart

Hampig Raphael Kourie, Oncology Department, Faculty of Medicine, Saint Joseph University, Beirut 880, Lebanon
Nicolas Mavroudakis, Philippe Aftimos, Martine Piccart, Oncology Department, Jules Bordet Institute, 1000 Brussels, Belgium

Author contributions: Kourie HR and Aftimos P initiated and wrote this case; Mavroudakis N and Piccart M reviewed and commented on this paper.

Institutional review board statement: The Bordet Institute’s Ethics Committee provides a favorable opinion on the disclosure/publication of a patient clinical history to be reported as a “case report”.

Informed consent statement: The authors undertake to respect the confidentiality, anonymity as well as the quality of the published information, The authors have recorded the consent of the patient in his medical record.

Conflict-of-interest statement: The authors confirm that they do not have any conflict of interest.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Correspondence to: Hampig Raphael Kourie, MD, MSc, Oncology Department, Faculty of Medicine, Saint Joseph University, Damascus Street, Beirut 880, Lebanon. hampig.kourie@usj.edu.lb
Telephone: +961-3-321899
Fax: +961-1-877787

Received: December 3, 2016
Peer-review started: December 5, 2016
First decision: February 17, 2017
Revised: July 24, 2017
Accepted: August 15, 2017
Article in press: August 16, 2017
Published online: October 10, 2017

Abstract
Charcot-Marie-Tooth (CMT) neuropathy is the most common hereditary cause of neuropathy. Diagnosis is usually not made during the childhood but in adolescence or late adulthood. It is reported in the literature that some neurotoxic chemotherapeutical agents can reveal an asymptomatic CMT IA hereditary neuropathy. To our knowledge, we report here the first case of CMT IA revealed in a 55-year-old woman after the administration of docetaxel/trastuzumab/pertuzumab for metastatic breast cancer. This case stresses again the necessity to obtain a complete personal and familial anamnesis and to perform a neurologic examination before the administration of neurotoxic chemotherapeutical agents to prevent the clinical expression of these hereditary neuropathies.

Key words: Charcot-Marie-Tooth IA; Docetaxel; Breast cancer; Neurotoxicity; Peripheral neuropathy

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: This case report represents the first case of Charcot-Marie-Tooth IA revealed after the administration of docetaxel/trastuzumab/pertuzumab for metastatic breast cancer. This paper will help to focus on the revelation of rare hereditary neuropathies after the administration of chemotherapies.
INTRODUCTION

Charcot-Marie-Tooth (CMT) type I neuropathy is the most common hereditary cause of neuropathy. Seventy percent to 80% of these patients present the subtype IA. This disease involves the motor and sensory peripheral nerves. Age of onset is variable; diagnosis is usually made between the age of 5 and 25 years. The diagnosis of CMT IA is confirmed with genetic testing and electro-diagnostic studies. There is no approved medical therapy to prevent the progression of CMT[1].

To our knowledge, we report here the first case of CMT IA revealed in a patient after receiving docetaxel/trastuzumab/pertuzumab for metastatic breast cancer. We first discuss the originality of our case and the potential role of chemotherapies in revealing or accentuating these syndromes. Then, we review the reported cases in the literature describing the relationship between these diseases and different chemotherapeutical agents.

CASE REPORT

We present the case of a 55-year-old patient, with unremarkable past medical history, who was diagnosed with HER2-positive and hormonal receptor positive stage IV metastatic breast cancer in 2014 with a primary tumor of 2.7 cm and one liver metastasis. Her first-line therapy consisted of the standard of care regimen docetaxel combined to trastuzumab and pertuzumab followed by surgery of the primary breast tumor and radiofrequency ablation of the unique metastatic hepatic lesion given an excellent response and the presence of oligometastatic disease.

Chemotherapy was stopped after 6 cycles of docetaxel and the patient was kept on maintenance therapy with trastuzumab and pertuzumab. Three months after the last cycle of chemotherapy, the patient developed numbness in the extremities, generalized depressed tendon reflexes, and hypoesthesia in the lower third of legs. At the clinical examination, pes cavus foot deformity, bilateral foot drop and generalized depressed tendon reflexes were detected.

After a complete anamnesis, the patient mentioned that many members of her family (her sister, her niece and her grand-father) were diagnosed with the CMT type IA disease. A genetic analysis of PMP22 gene confirmed the diagnosis in our patient and conduction velocity studies demonstrated demyelinating abnormalities concordant with the diagnosis. In fact, multiple ligation-dependent probe amplification of the exons 1-5 of the PMP22 gene located at 17p11.2 showed genomic duplication comprising the PMP22 gene.

The patient continued her treatment for breast cancer based on targeted therapies (pertuzumab and trastuzumab) and hormonal therapy (letrozole) and is currently in complete remission. For her stable persistent neurologic deficits physiotherapy was prescribed for maintaining posture and balance, genetic counseling for the family members, namely her two sons, and avoidance of neurotoxic drugs.

DISCUSSION

Neurologic toxicities represent the second most frequent chemotherapy-induced side effect after hematologic toxicities. Vinca-alkaloids, taxanes and platinum-based agents are the most frequent drugs inducing peripheral neurotoxicity. These drugs are used in the treatment of ovarian, breast, lung, prostate, colon and hematological malignancies. Chemotherapy-induced neuropathy is usually dose-dependent. Patients with pre-existing neuropathic symptoms due to diabetes, hereditary neuropathies or earlier treatment with neurotoxic chemotherapy are probably more vulnerable to further development of chemotherapy-induced peripheral neuropathy[2,3].

We report, here, an interesting case of a hereditary CMT IA disease revealed after the administration of docetaxel in combination with anti-HER2 antibodies, in an advanced HER2-positive breast cancer. Our case represents the first case of CMT IA revealed after the administration of docetaxel. It is less likely that this disease was revealed by trastuzumab or pertuzumab, because it was not reported in the literature any CMT related to biologic agents.

A case of an aggravation of CMT after the administration of carboplatin and paclitaxel for ovarian cancer was reported before; the symptomatology resolved after the replacement of paclitaxel by docetaxel, considered as less neurotoxic. 4. Thus, our case demonstrates that even less neurotoxic taxanes, as docetaxel, can sometimes reveal or worsen CMT neuropathies.

In some cases, CMT IA has been diagnosed after the administration of neurotoxic drugs including chemotherapeutical agents, mainly vincristine. The cases reported in the literature are summarized in Table 1.

A retrospective case series, in three families with known hereditary neuropathies treated with vincristine, concluded that vincristine in patients with 17p11.2-12 may lead to severe neurotoxicity from vincristine and that this drug should not be administered in patients with CMT1A[13]. On the other hand, a recent study of the Mayo Clinic investigated the association of non-CMT polyneuropathy with CMT genes in patients treated with paclitaxel. The results demonstrated a relationship between the CMT gene allelic variability and the susceptibility to chemotherapy-induced peripheral neuropathy[16].

This case stresses again the importance for on-
Table 1 Summary of all the reported cases in the literature of Charcot-Marie-Tooth revealed after administration of chemotherapy

| Ref. | Patient characteristics | Drug | Malignancy | Signs and symptoms | Diagnosis |
|------|-------------------------|------|------------|-------------------|----------|
| Uno et al[7], 1999 | 44 M | Vincristine | NHL | Rapid and marked weakening progressing to quadriplegia and bulbar palsy pes cavus (hollow foot) | Slower nerve conduction velocity 17p11.2-12 duplication |
| Martino et al[13], 2005 | F | Paclitaxel/Carboplatin | Ovarian cancer | Distal sensory and motor neuropathy; Unable to walk, write, or drive | Already diagnosed |
| Hildebrandt et al[8], 2000 | 52 F | Vincristine | NHL | Dyshphagia, dysarthria, muscular weakness of both lower and upper extremities, areflexia, paraesthesia of the fingertips and bilateral sensory impairment of feet and lower legs | Peripheral axonal and demyelinating sensorimotor neuropathy 17p11.2 duplication |
| Graf et al[5], 1996 | 9 F | Vincristine | Acute lymphoblastic leukemia | Severe acquired weakness, areflexia and distal muscle atrophy | 17p duplication |
| | 18 F | | Burkitt lymphoma | Pes cavus, distal muscle atrophy and weakness, stocking glove sensory deficits | 17p duplication |
| | 46 M | | Testicular embryonal cell carcinoma | Foot drop, pes cavus and areflexia, marked weakness | Slow motor nerve conduction velocity |

NHL: Non-Hodgkin lymphoma; M: Male; F: Female.

The patient presented numbness in the extremities, generalized depressed tendon reflexes, and hypesthesia in the lower third of legs, 3 mo after the last cycle of chemotherapy.

The clinical examination of the patient revealed pes cavus foot deformity, bilateral foot drop and generalized depressed tendon reflexes.

Acute myelitis or Guillain-Barré syndrome are possible differential diagnosis.

A multiple ligation-dependent probe amplification of the exons 1-5 of the PMP22 gene located at 17p11.2 showed genomic duplication comprising the 17p11.2-12 duplication gene.

Pathological diagnosis was not necessary.

Physiotherapy was prescribed for maintaining posture and balance, genetic counseling for the family members, namely her two sons, and avoidance of neurotoxic drugs.

Perform a complete anamnesis on past personal and familial history, before the administration of a neurotoxic chemotherapeutical regimen. Perform a complete neurological examination before administering neurotoxic chemotherapies to avoid the worsening of non-diagnosed peripheral neuropathies.

This manuscript presents the first case of Charcot-Marie-Tooth disease identified after the administration of docetaxel in combination with anti-HER2 antibodies. This is an important and interesting report of a rare case.

REFERENCES
1 Bird TD. Charcot-Marie-Tooth Neuropathy X Type 1. In: Bird TD, Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, McFarland H, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle, 1993-2017 [PMID: 20301548]
2 Verstappen CC, Heimans JJ, Hoekman K, Postma TJ. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 2003; 63: 1549-1563 [PMID: 12887262 DOI: 10.2165/00003495-200363150-00003]
3 Windebank AJ, Grisol W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008; 13: 27-46 [PMID: 18346229 DOI: 10.1111/j.1529-8027.2008.00156.x]
4 Martino MA; Miller E, Grendys EC Jr. The administration of neurotoxic chemotherapies to already diagnosed hereditary peripheral neuropathies. *Ann Neurol* 1996; 40: 414-419 [PMID: 8109089]
5 Uno S, Katayama K, Dobushi N, Hirano A, Oghara A, Yamazaki H, Usui N, Kobayashi T, Isobe K, Kuriashi Y. [Acute vincristine neurotoxicity in a non-Hodgkin’s lymphoma patient with Charcot-Marie-Tooth disease]. Rinsho Ketsueki 1999; 40: 242-247 [PMID: 10390891]
Kourie HR et al. Charcot-Marie-Tooth revealed after docetaxel

Ann Oncol 2000; 11: 743-747 [PMID: 10942065 DOI: 10.1023/A:1008369315240]

P-Reviewer: Hosseini M, Vetvicka V, Yamashita H
S-Editor: Kong JX
L-Editor: A
E-Editor: Lu YJ
